We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study.
- Authors
BERGENSTAL, RICHARD M.; TAMBORLANE, WILLIAM V.; AHMANN, ANDREW; BUSE, JOHN B.; DAILEY, GEORGE; DAVIS, STEPHEN N.; JOYCE, CAROL; PERKINS, BRUCE A.; WELSH, JOHN B.; WILLI, STEVEN M.; WOOD, MICHAEL A.
- Abstract
OBJECTIVE--To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS--The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS--A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P<0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P<0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS--Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
- Subjects
INJECTIONS; GLYCEMIC index; THERAPEUTICS; DETECTORS; CLINICAL medicine
- Publication
Diabetes Care, 2011, Vol 34, Issue 11, p2403
- ISSN
0149-5992
- Publication type
Article
- DOI
10.2337/dc11-1248